Status:

WITHDRAWN

Adalat XL vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients

Lead Sponsor:

Bayer

Conditions:

Diabetic Nephropathies

Hypertension

Eligibility:

All Genders

18-80 years

Phase:

PHASE3

Brief Summary

The study consists of a 12 week run-in period when all subjects are stabilized on a single dose of Avalide (300 mg/12.5 mg or 300mg/25mg dose) per day. After this 12 week run-in ends, subjects will be...

Eligibility Criteria

Inclusion

  • \>/= 18 and \< 80 years old.
  • Diagnosed with hypertension.
  • Diagnosed with diabetes mellitus type 2 for at least 6 mths prior to entry and on stable medication for diabetes for at 1 mth prior to screening.
  • Treated on ARB, ACE inhibitor with or without hydrochlorothiazide and suitable to receive combination therapy with Avalide at 300mg/12.5mg per day or 300mg/25mg per day.
  • Diagnosed with diabetic nephropathy and have proteinuria between 0.8g/day and 5.0g/day at screening and then between 0.8g/day and 3.0g/day at randomization.
  • Medically appropriate to receive Adalat XL or Tiazac XC.

Exclusion

  • History of alcohol or substance abuse.
  • Significant CV disorder such as ischemic heart disease, arrhythmias within the last 6 mths, or any history of severe congestive heart failure.
  • Myocarditis or pericarditis within last 30 day of screening.
  • ECG showing evidence of major arrhythmia or conduction disturbances requiring treatment with anti-arrhythmic medication.
  • Females with child-bearing potential or males with a partner of child-bearing potential unless willing to use effective contraception during the study and 3 mths after the end of study.
  • Females who are pregnant, lactating or planning pregnancy during the study and for 3 mths after the study end.
  • Known hypersensitivity to Adalat XL or Tiazac XC or other calcium channel blockers of the dihydropyridine class.
  • Resting heart rate \<50 or \>110 bpm.
  • Presence of secondary or malignant hypertension.
  • DBP \>/= 180 and/or SBP \>/= 110 mmHg.

Key Trial Info

Start Date :

November 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2009

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00713011

Start Date

November 1 2008

End Date

March 1 2009

Last Update

November 16 2012

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.